This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gadgeel, S. M. Articles by LoRusso, P. M. Search for Related Content PubMed PubMed Citation Articles by Gadgeel, S. M. Articles by LoRusso, P. M.

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

Authors' Affiliations: ¹ Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; ² National Cancer Institute, Cancer Therapy Evaluation Program; and ³ Bristol-Myers Squibb, Princeton, New Jersey

Requests for reprints: Patricia M. LoRusso, Division of Hematology-Oncology, 4HWCRC, 4100 John R, Detroit, MI 48201. E-mail: lorussop{at}karmanos.org.

Purpose: BMS-247550 is a semisynthetic derivative of epothilone B with mechanism of action analogous to paclitaxel. It has shown impressive antitumor activity in preclinical studies including in taxane-resistant models. We conducted a phase I trial, based on accelerated titration "2B" design, of BMS-247550 given as a 1-hour infusion every 3 weeks.

Experimental Design: Seventeen patients (M:F, 10:7; median age, 54 years; performance status, 0-2) were treated on the trial. Forty-five cycles (1-9 cycles) of BMS-247550 were given at dosages ranging from 7.4 to 56 mg/m². All patients received prophylaxis for hypersensitivity reactions, related to Cremophor-EL, with steroids and histamine antagonists.

Results: First-course dose-limiting toxicity (DLT) was observed in two of three patients at 56 mg/m² (neutropenic sepsis, prolonged grade 4 neutropenia) and in one of six patients at 40 mg/m². Nonhematologic grade 3 to 4 toxicities observed were emesis and fatigue and they occurred only at 56 mg/m². Grade 1 to 2 peripheral neuropathy was also observed. Other grade 1 to 2 toxicities were myalgias, arthralgias, rash, hand/foot syndrome, and mucositis. AUC and C_max seemed proportional to the dose and the DLT. Development of neutropenia with BMS-247550 is related to the duration of drug exposure above a threshold.

Conclusions: The maximum tolerated dose (MTD) of BMS-247550 is 40 mg/m² given every 3 weeks. Neutropenia is the DLT. The accelerated titration "2B" design may help in determining MTD with fewer patients enrolled and more being treated closer to the MTD. However, the accelerated titration design did not seem to shorten the study duration.

This article has been cited by other articles:

				B. A. Burtness, J. Manola, R. Axelrod, A. Argiris, and A. A. Forastiere A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study Ann. Onc., May 1, 2008; 19(5): 977 - 983. [Abstract] [Full Text] [PDF]

				S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al. The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709. [Abstract] [Full Text] [PDF]

				C Sessa, A Perotti, A Llado, S Cresta, G Capri, M Voi, S Marsoni, I Corradino, and L Gianni Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule Ann. Onc., September 1, 2007; 18(9): 1548 - 1553. [Abstract] [Full Text] [PDF]

				E. Thomas, J. Tabernero, M. Fornier, P. Conte, P. Fumoleau, A. Lluch, L. T. Vahdat, C. A. Bunnell, H. A. Burris, P. Viens, et al. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer J. Clin. Oncol., August 10, 2007; 25(23): 3399 - 3406. [Abstract] [Full Text] [PDF]

				C. Aghajanian, H. A. Burris III, S. Jones, D. R. Spriggs, M. B. Cohen, R. Peck, P. Sabbatini, M. L. Hensley, F. A. Greco, J. Dupont, et al. Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients With Advanced Solid Tumors and Lymphomas J. Clin. Oncol., March 20, 2007; 25(9): 1082 - 1088. [Abstract] [Full Text] [PDF]

				J. Cortes and J. Baselga Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones Oncologist, March 1, 2007; 12(3): 271 - 280. [Abstract] [Full Text] [PDF]